ID   BIRC5_HUMAN             Reviewed;         142 AA.
AC   O15392; A2SUH6; B2R4R1; Q2I3N8; Q4VGX0; Q53F61; Q5MGC6; Q6FHL2; Q75SP2;
AC   Q9P2W8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2012, sequence version 3.
DT   18-JUN-2025, entry version 251.
DE   RecName: Full=Baculoviral IAP repeat-containing protein 5;
DE   AltName: Full=Apoptosis inhibitor 4;
DE   AltName: Full=Apoptosis inhibitor survivin;
GN   Name=BIRC5; Synonyms=API4, IAP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9256286; DOI=10.1038/nm0897-917;
RA   Ambrosini G., Adida C., Altieri D.C.;
RT   "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.";
RL   Nat. Med. 3:917-921(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10626797;
RA   Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.;
RT   "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the
RT   apoptosis inhibitor survivin with different antiapoptotic properties.";
RL   Cancer Res. 59:6097-6102(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RX   PubMed=11084331; DOI=10.1016/s0960-9822(00)00769-7;
RA   Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L.,
RA   Choo K.H.;
RT   "Survivin and the inner centromere protein INCENP show similar cell-cycle
RT   localization and gene knockout phenotype.";
RL   Curr. Biol. 10:1319-1328(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Myeloid leukemia cell;
RX   PubMed=14741722; DOI=10.1016/j.bbrc.2003.12.178;
RA   Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T.,
RA   Inuzuka M.;
RT   "Identification of a novel splice variant of the human anti-apoptosis gene
RT   survivin.";
RL   Biochem. Biophys. Res. Commun. 314:902-907(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary cancer;
RX   PubMed=16329164; DOI=10.1080/10425170500226490;
RA   Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S.;
RT   "Molecular cloning and bioinformatics analysis of a novel spliced variant
RT   of survivin from human breast cancer cells.";
RL   DNA Seq. 16:321-328(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Neuroblastoma;
RA   Kageyama H., Islam A., Takayasu H., Nakagawara A.;
RT   "An isoform of survivin (survivin-beta) which has 23 amino acids insertion
RT   into the BIR domain.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RA   Caldas H., Honsey L.E., Altura R.A.;
RT   "Survivin 2 alpha: a novel survivin splice variant expressed in human
RT   malignancies.";
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RC   TISSUE=Myeloid leukemia cell;
RA   Vietri M.T., Cioffi M., Sessa M., Sica V., Molinari A.M.;
RT   "Identification of a novel survivin splicing variant 3alpha in acute
RT   myeloid leukemia.";
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-129.
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, Mammary gland, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   FUNCTION.
RX   PubMed=9859993; DOI=10.1038/25141;
RA   Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C.,
RA   Altieri D.C.;
RT   "Control of apoptosis and mitotic spindle checkpoint by survivin.";
RL   Nature 396:580-584(1998).
RN   [17]
RP   PHOSPHORYLATION AT THR-34.
RX   PubMed=11069302; DOI=10.1073/pnas.240390697;
RA   O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A.,
RA   Tognin S., Marchisio P.C., Altieri D.C.;
RT   "Regulation of apoptosis at cell division by p34cdc2 phosphorylation of
RT   survivin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:13103-13107(2000).
RN   [18]
RP   FUNCTION IN APOPTOSIS SUPPRESSION, INTERACTION WITH LAMTOR5/HBXIP,
RP   MUTAGENESIS OF THR-34, AND SUBCELLULAR LOCATION.
RX   PubMed=12773388; DOI=10.1093/emboj/cdg263;
RA   Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I.,
RA   Reed J.C.;
RT   "HBXIP functions as a cofactor of survivin in apoptosis suppression.";
RL   EMBO J. 22:2729-2740(2003).
RN   [19]
RP   INTERACTION WITH INCENP, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-117,
RP   AND MUTAGENESIS OF THR-117.
RX   PubMed=14610074; DOI=10.1074/jbc.m311299200;
RA   Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.;
RT   "Aurora-B phosphorylation in vitro identifies a residue of survivin that is
RT   essential for its localization and binding to inner centromere protein
RT   (INCENP) in vivo.";
RL   J. Biol. Chem. 279:5655-5660(2004).
RN   [20]
RP   INTERACTION WITH CDCA8.
RX   PubMed=15249581; DOI=10.1083/jcb.200404001;
RA   Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R.,
RA   Nigg E.A., Gerloff D.L., Earnshaw W.C.;
RT   "Borealin: a novel chromosomal passenger required for stability of the
RT   bipolar mitotic spindle.";
RL   J. Cell Biol. 166:179-191(2004).
RN   [21]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH BIRC2/C-IAP1.
RX   PubMed=15665297; DOI=10.1158/0008-5472.210.65.1;
RA   Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.;
RT   "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle.";
RL   Cancer Res. 65:210-218(2005).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=16344111; DOI=10.1016/s0074-7696(05)47002-3;
RA   Wheatley S.P., McNeish I.A.;
RT   "Survivin: a protein with dual roles in mitosis and apoptosis.";
RL   Int. Rev. Cytol. 247:35-88(2005).
RN   [23]
RP   FUNCTION, INTERACTION WITH USP9X, SUBCELLULAR LOCATION, UBIQUITINATION, AND
RP   MUTAGENESIS OF LYS-23; LYS-62; LYS-78 AND LYS-79.
RX   PubMed=16322459; DOI=10.1126/science.1120160;
RA   Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.;
RT   "Chromosome alignment and segregation regulated by ubiquitination of
RT   survivin.";
RL   Science 310:1499-1504(2005).
RN   [24]
RP   MUTAGENESIS OF ASP-70; ASP-71 AND 70-ASP--ASP-71.
RX   PubMed=16762323; DOI=10.1016/j.bbrc.2006.05.131;
RA   Cao L., Yan X., Wu Y., Hu H., Li Q., Zhou T., Jiang S., Yu L.;
RT   "Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin
RT   with Aurora B and causes multinucleation in HeLa cells.";
RL   Biochem. Biophys. Res. Commun. 346:400-407(2006).
RN   [25]
RP   INTERACTION WITH CDCA8.
RX   PubMed=16239925; DOI=10.1038/sj.embor.7400562;
RA   Vader G., Kauw J.J.W., Medema R.H., Lens S.M.A.;
RT   "Survivin mediates targeting of the chromosomal passenger complex to the
RT   centromere and midbody.";
RL   EMBO Rep. 7:85-92(2006).
RN   [26]
RP   INTERACTION WITH CDCA8.
RX   PubMed=16427043; DOI=10.1016/j.yexcr.2005.12.015;
RA   Chang J.-L., Chen T.-H., Wang C.-F., Chiang Y.-H., Huang Y.-L., Wong F.-H.,
RA   Chou C.-K., Chen C.-M.;
RT   "Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein
RT   and its nuclear accumulation is linked to poor prognosis for human gastric
RT   cancer.";
RL   Exp. Cell Res. 312:962-973(2006).
RN   [27]
RP   INTERACTION WITH EVI5.
RX   PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032;
RA   Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.;
RT   "EVI5 protein associates with the INCENP-aurora B kinase-survivin
RT   chromosomal passenger complex and is involved in the completion of
RT   cytokinesis.";
RL   Exp. Cell Res. 312:2325-2335(2006).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH CDCA8.
RX   PubMed=16291752; DOI=10.1074/jbc.m508773200;
RA   Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P.,
RA   Wheatley S.P.;
RT   "Molecular analysis of survivin isoforms: evidence that alternatively
RT   spliced variants do not play a role in mitosis.";
RL   J. Biol. Chem. 281:1286-1295(2006).
RN   [29]
RP   INTERACTION WITH CDCA8.
RX   PubMed=16436504; DOI=10.1091/mbc.e05-08-0727;
RA   Lens S.M.A., Rodriguez J.A., Vader G., Span S.W., Giaccone G., Medema R.H.;
RT   "Uncoupling the central spindle-associated function of the chromosomal
RT   passenger complex from its role at centromeres.";
RL   Mol. Biol. Cell 17:1897-1909(2006).
RN   [30]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled by
RT   BRUCE.";
RL   Cell 132:832-845(2008).
RN   [31]
RP   INDUCTION.
RX   PubMed=17993464; DOI=10.1074/jbc.m704035200;
RA   Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.;
RT   "Cartilage oligomeric matrix protein protects cells against death by
RT   elevating members of the IAP family of survival proteins.";
RL   J. Biol. Chem. 283:648-659(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-34, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [33]
RP   FUNCTION, INTERACTION WITH RAN; AURKB AND CDCA8, SUBCELLULAR LOCATION,
RP   DEVELOPMENTAL STAGE, AND MUTAGENESIS OF GLU-65.
RX   PubMed=18591255; DOI=10.1128/mcb.02039-07;
RA   Xia F., Canovas P.M., Guadagno T.M., Altieri D.C.;
RT   "A survivin-ran complex regulates spindle formation in tumor cells.";
RL   Mol. Cell. Biol. 28:5299-5311(2008).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=21364656; DOI=10.1038/cddis.2010.25;
RA   Knauer S.K., Heinrich U.R., Bier C., Habtemichael N., Docter D.,
RA   Helling K., Mann W.J., Stauber R.H.;
RT   "An otoprotective role for the apoptosis inhibitor protein survivin.";
RL   Cell Death Dis. 1:E51-E51(2010).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3 AND XPO1/CRM1,
RP   ACETYLATION AT LYS-23; LYS-90; LYS-110; LYS-112; LYS-115; LYS-121 AND
RP   LYS-129, MUTAGENESIS OF LYS-129, AND CHARACTERIZATION OF VARIANT GLU-129.
RX   PubMed=20826784; DOI=10.1074/jbc.m110.152777;
RA   Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A.,
RA   Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.;
RT   "Acetylation directs survivin nuclear localization to repress STAT3
RT   oncogenic activity.";
RL   J. Biol. Chem. 285:36129-36137(2010).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=20627126; DOI=10.1016/j.mcn.2010.07.003;
RA   Habtemichael N., Heinrich U.R., Knauer S.K., Schmidtmann I., Bier C.,
RA   Docter D., Brochhausen C., Helling K., Brieger J., Stauber R.H., Mann W.J.;
RT   "Expression analysis suggests a potential cytoprotective role of Birc5 in
RT   the inner ear.";
RL   Mol. Cell. Neurosci. 45:297-305(2010).
RN   [37]
RP   FUNCTION, HISTONE-BINDING, AND MUTAGENESIS OF ARG-18; TRP-25; CYS-33;
RP   CYS-57 AND TRP-67.
RX   PubMed=20929775; DOI=10.1126/science.1194498;
RA   Yamagishi Y., Honda T., Tanno Y., Watanabe Y.;
RT   "Two histone marks establish the inner centromere and chromosome bi-
RT   orientation.";
RL   Science 330:239-243(2010).
RN   [38]
RP   PHOSPHORYLATION AT THR-48, AND MUTAGENESIS OF THR-48.
RX   PubMed=21252625; DOI=10.4161/cc.10.3.14758;
RA   Barrett R.M., Colnaghi R., Wheatley S.P.;
RT   "Threonine 48 in the BIR domain of survivin is critical to its mitotic and
RT   anti-apoptotic activities and can be phosphorylated by CK2 in vitro.";
RL   Cell Cycle 10:538-548(2011).
RN   [39]
RP   INTERACTION WITH JTB.
RX   PubMed=21225229; DOI=10.3892/ijo.2011.900;
RA   Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.;
RT   "PAR, a protein involved in the cell cycle, is functionally related to
RT   chromosomal passenger proteins.";
RL   Int. J. Oncol. 38:777-785(2011).
RN   [40]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH XIAP/BIRC4 AND DIABLO/SMAC.
RX   PubMed=21536684; DOI=10.1074/jbc.m111.237586;
RA   Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V.,
RA   Kopantzev E.P., Shakhparonov M.I.;
RT   "Survivin monomer plays an essential role in apoptosis regulation.";
RL   J. Biol. Chem. 286:23296-23307(2011).
RN   [41]
RP   PHOSPHORYLATION AT THR-34 BY CDK15.
RX   PubMed=24866247; DOI=10.1016/j.bbrc.2014.05.070;
RA   Park M.H., Kim S.Y., Kim Y.J., Chung Y.H.;
RT   "ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing
RT   phosphorylation of survivin Thr34.";
RL   Biochem. Biophys. Res. Commun. 450:129-134(2014).
RN   [42]
RP   UBIQUITINATION.
RX   PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046;
RA   Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.;
RT   "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin
RT   to maintain genome integrity.";
RL   Mol. Cell 54:805-819(2014).
RN   [43]
RP   FUNCTION, INTERACTION WITH FBXL7, AND MUTAGENESIS OF 90-LYS-LYS-91 AND
RP   GLU-126.
RX   PubMed=25778398; DOI=10.1074/jbc.m114.629931;
RA   Liu Y., Lear T., Iannone O., Shiva S., Corey C., Rajbhandari S., Jerome J.,
RA   Chen B.B., Mallampalli R.K.;
RT   "The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by
RT   Mediating the Ubiquitylation and Proteasomal Degradation of Survivin.";
RL   J. Biol. Chem. 290:11843-11852(2015).
RN   [44]
RP   SUBUNIT, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=27332895; DOI=10.1371/journal.pone.0157305;
RA   Sasai K., Katayama H., Hawke D.H., Sen S.;
RT   "Aurora-C interactions with survivin and INCENP reveal shared and distinct
RT   features compared with Aurora-B chromosome passenger protein complex.";
RL   PLoS ONE 11:E0157305-E0157305(2016).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH FBXL7.
RX   PubMed=28218735; DOI=10.1038/oncsis.2016.80;
RA   Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W.,
RA   Liu Q.;
RT   "Aurora kinase A regulates Survivin stability through targeting FBXL7 in
RT   gastric cancer drug resistance and prognosis.";
RL   Oncogenesis 6:E298-E298(2017).
RN   [46]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS EBNA1 (MICROBIAL INFECTION).
RX   PubMed=28077791; DOI=10.18632/oncotarget.14540;
RA   Dheekollu J., Malecka K., Wiedmer A., Delecluse H.J., Chiang A.K.,
RA   Altieri D.C., Messick T.E., Lieberman P.M.;
RT   "Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal
RT   latency.";
RL   Oncotarget 8:7248-7264(2017).
RN   [47]
RP   DEUBIQUITINATION BY USP35 AND USP38.
RX   PubMed=34438346; DOI=10.1016/j.bbrc.2021.08.050;
RA   Wang W., Lin H., Zheng E., Hou Z., Liu Y., Huang W., Chen D., Feng J.,
RA   Li J., Li L.;
RT   "Regulation of survivin protein stability by USP35 is evolutionarily
RT   conserved.";
RL   Biochem. Biophys. Res. Commun. 574:48-55(2021).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF ISOFORM 1.
RX   PubMed=10949039; DOI=10.1016/s1097-2765(05)00020-1;
RA   Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O.,
RA   Margolis R.L.;
RT   "Crystal structure of human survivin reveals a bow tie-shaped dimer with
RT   two unusual alpha-helical extensions.";
RL   Mol. Cell 6:183-189(2000).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF ISOFORM 1.
RX   PubMed=10876248; DOI=10.1038/76838;
RA   Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P.;
RT   "Structure of the human anti-apoptotic protein survivin reveals a dimeric
RT   arrangement.";
RL   Nat. Struct. Biol. 7:602-608(2000).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT,
RP   AND INTERACTION WITH CDCA8 AND INCENP.
RX   PubMed=17956729; DOI=10.1016/j.cell.2007.07.045;
RA   Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.;
RT   "Structure of a Survivin-Borealin-INCENP core complex reveals how
RT   chromosomal passengers travel together.";
RL   Cell 131:271-285(2007).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=19530738; DOI=10.1021/bi900530v;
RA   Bourhis E., Lingel A., Phung Q., Fairbrother W.J., Cochran A.G.;
RT   "Phosphorylation of a borealin dimerization domain is required for proper
RT   chromosome segregation.";
RL   Biochemistry 48:6783-6793(2009).
CC   -!- FUNCTION: Multitasking protein that has dual roles in promoting cell
CC       proliferation and preventing apoptosis (PubMed:20627126,
CC       PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993).
CC       Component of a chromosome passage protein complex (CPC) which is
CC       essential for chromosome alignment and segregation during mitosis and
CC       cytokinesis (PubMed:16322459). Acts as an important regulator of the
CC       localization of this complex; directs CPC movement to different
CC       locations from the inner centromere during prometaphase to midbody
CC       during cytokinesis and participates in the organization of the center
CC       spindle by associating with polymerized microtubules (PubMed:20826784).
CC       Involved in the recruitment of CPC to centromeres during early mitosis
CC       via association with histone H3 phosphorylated at 'Thr-3' (H3pT3)
CC       during mitosis (PubMed:20929775). The complex with RAN plays a role in
CC       mitotic spindle formation by serving as a physical scaffold to help
CC       deliver the RAN effector molecule TPX2 to microtubules
CC       (PubMed:18591255). May counteract a default induction of apoptosis in
CC       G2/M phase (PubMed:9859993). The acetylated form represses STAT3
CC       transactivation of target gene promoters (PubMed:20826784). May play a
CC       role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7
CC       (PubMed:21536684). Essential for the maintenance of mitochondrial
CC       integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do
CC       not appear to play vital roles in mitosis (PubMed:12773388,
CC       PubMed:16291752). Isoform 3 shows a marked reduction in its anti-
CC       apoptotic effects when compared with the displayed wild-type isoform
CC       (PubMed:10626797). {ECO:0000269|PubMed:10626797,
CC       ECO:0000269|PubMed:12773388, ECO:0000269|PubMed:16291752,
CC       ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18591255,
CC       ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784,
CC       ECO:0000269|PubMed:20929775, ECO:0000269|PubMed:21364656,
CC       ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398,
CC       ECO:0000269|PubMed:28218735, ECO:0000269|PubMed:9859993}.
CC   -!- SUBUNIT: Monomer or homodimer. Exists as a homodimer in the apo state
CC       and as a monomer in the CPC-bound state. The monomer protects cells
CC       against apoptosis more efficiently than the dimer. Only the dimeric
CC       form is capable of enhancing tubulin stability in cells. When
CC       phosphorylated, interacts with LAMTOR5/HBXIP; the resulting complex
CC       binds pro-CASP9, as well as active CASP9, but much less efficiently.
CC       Component of the chromosomal passenger complex (CPC) composed of at
CC       least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in the
CC       complex forms a triple-helix bundle-based subcomplex with INCENP and
CC       CDCA8 (PubMed:17956729). Interacts with JTB. Interacts (via BIR domain)
CC       with histone H3 phosphorylated at 'Thr-3' (H3pT3). Interacts with EVI5.
CC       Interacts with GTP-bound RAN in both the S and M phases of the cell
CC       cycle. Interacts with USP9X. Interacts with tubulin. Interacts with
CC       BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The
CC       monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The
CC       monomeric form interacts with XIAP/BIRC4. Both the dimeric and
CC       monomeric form can interact with DIABLO/SMAC. Interacts with
CC       BIRC6/bruce. Interacts with FBXL7; this interaction facilitates the
CC       polyubiquitination and subsequent proteasomal degradation of BIRC5 by
CC       the SCF(FBXL7) E3 ubiquitin-protein ligase complex (PubMed:25778398,
CC       PubMed:28218735). {ECO:0000269|PubMed:12773388,
CC       ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:15249581,
CC       ECO:0000269|PubMed:15665297, ECO:0000269|PubMed:16239925,
CC       ECO:0000269|PubMed:16291752, ECO:0000269|PubMed:16322459,
CC       ECO:0000269|PubMed:16427043, ECO:0000269|PubMed:16436504,
CC       ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729,
CC       ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18591255,
CC       ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21225229,
CC       ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398,
CC       ECO:0000269|PubMed:28218735}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus (EBV)
CC       EBNA1; this interaction is probably important for EBV episome
CC       maintenance in Burkitt's lymphoma cells. {ECO:0000269|PubMed:28077791}.
CC   -!- INTERACTION:
CC       O15392; Q92870-2: APBB2; NbExp=3; IntAct=EBI-518823, EBI-21535880;
CC       O15392; P05067: APP; NbExp=3; IntAct=EBI-518823, EBI-77613;
CC       O15392; P05067-2: APP; NbExp=3; IntAct=EBI-518823, EBI-17264467;
CC       O15392; O14965: AURKA; NbExp=2; IntAct=EBI-518823, EBI-448680;
CC       O15392; Q96GD4: AURKB; NbExp=13; IntAct=EBI-518823, EBI-624291;
CC       O15392; Q9UQB9: AURKC; NbExp=10; IntAct=EBI-518823, EBI-3926851;
CC       O15392; Q14457: BECN1; NbExp=3; IntAct=EBI-518823, EBI-949378;
CC       O15392; O15392: BIRC5; NbExp=2; IntAct=EBI-518823, EBI-518823;
CC       O15392; Q15834: CCDC85B; NbExp=3; IntAct=EBI-518823, EBI-739674;
CC       O15392; Q53HL2: CDCA8; NbExp=21; IntAct=EBI-518823, EBI-979174;
CC       O15392; P06493: CDK1; NbExp=6; IntAct=EBI-518823, EBI-444308;
CC       O15392; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-518823, EBI-25840379;
CC       O15392; Q9NR28: DIABLO; NbExp=2; IntAct=EBI-518823, EBI-517508;
CC       O15392; Q86XJ1: GAS2L3; NbExp=4; IntAct=EBI-518823, EBI-9248152;
CC       O15392; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-518823, EBI-11110431;
CC       O15392; P42858: HTT; NbExp=15; IntAct=EBI-518823, EBI-466029;
CC       O15392; Q9NQS7: INCENP; NbExp=11; IntAct=EBI-518823, EBI-307907;
CC       O15392; O43504: LAMTOR5; NbExp=3; IntAct=EBI-518823, EBI-713382;
CC       O15392; Q96CV9: OPTN; NbExp=3; IntAct=EBI-518823, EBI-748974;
CC       O15392; Q7Z412: PEX26; NbExp=3; IntAct=EBI-518823, EBI-752057;
CC       O15392; Q9BXM7: PINK1; NbExp=3; IntAct=EBI-518823, EBI-2846068;
CC       O15392; P62826: RAN; NbExp=7; IntAct=EBI-518823, EBI-286642;
CC       O15392; P37840: SNCA; NbExp=3; IntAct=EBI-518823, EBI-985879;
CC       O15392; Q13148: TARDBP; NbExp=6; IntAct=EBI-518823, EBI-372899;
CC       O15392; P09936: UCHL1; NbExp=3; IntAct=EBI-518823, EBI-714860;
CC       O15392; O14980: XPO1; NbExp=2; IntAct=EBI-518823, EBI-355867;
CC       O15392-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518838, EBI-624291;
CC       O15392-1; O15392-1: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518838;
CC       O15392-1; O15392-2: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518842;
CC       O15392-1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518838, EBI-979174;
CC       O15392-2; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518842, EBI-624291;
CC       O15392-2; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518842, EBI-979174;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20627126,
CC       ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21364656}. Nucleus
CC       {ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784,
CC       ECO:0000269|PubMed:21364656}. Chromosome {ECO:0000269|PubMed:14610074}.
CC       Chromosome, centromere {ECO:0000269|PubMed:11084331,
CC       ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:16322459}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000269|PubMed:11084331}. Chromosome,
CC       centromere, kinetochore {ECO:0000269|PubMed:11084331}. Midbody
CC       {ECO:0000269|PubMed:15665297}. Note=Localizes at the centromeres from
CC       prophase to metaphase, at the spindle midzone during anaphase and a the
CC       midbody during telophase and cytokinesis. Accumulates in the nucleus
CC       upon treatment with leptomycin B (LMB), a XPO1/CRM1 nuclear export
CC       inhibitor (By similarity). Localizes on chromosome arms and inner
CC       centromeres from prophase through metaphase. Localizes to kinetochores
CC       in metaphase, distributes to the midzone microtubules in anaphase and
CC       at telophase, localizes exclusively to the midbody (PubMed:11084331).
CC       Colocalizes with AURKB at mitotic chromosomes (PubMed:14610074).
CC       Acetylation at Lys-129 directs its localization to the nucleus by
CC       enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated
CC       nuclear export (PubMed:20826784). {ECO:0000250|UniProtKB:E3SCZ8,
CC       ECO:0000269|PubMed:11084331, ECO:0000269|PubMed:14610074,
CC       ECO:0000269|PubMed:20826784}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=O15392-1; Sequence=Displayed;
CC       Name=2; Synonyms=2B, Beta;
CC         IsoId=O15392-2; Sequence=VSP_002454;
CC       Name=3; Synonyms=DeltaEx3;
CC         IsoId=O15392-3; Sequence=VSP_020338;
CC       Name=4; Synonyms=3B;
CC         IsoId=O15392-4; Sequence=VSP_020342;
CC       Name=5; Synonyms=SI;
CC         IsoId=O15392-5; Sequence=VSP_020341;
CC       Name=6; Synonyms=3 alpha;
CC         IsoId=O15392-6; Sequence=VSP_020339;
CC       Name=7; Synonyms=2 alpha;
CC         IsoId=O15392-7; Sequence=VSP_020340;
CC   -!- TISSUE SPECIFICITY: Expressed only in fetal kidney and liver, and to
CC       lesser extent, lung and brain (PubMed:10626797). Abundantly expressed
CC       in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in
CC       high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed
CC       in various renal cell carcinoma cell lines (PubMed:10626797). Expressed
CC       in cochlea including the organ of Corti, the lateral wall, the
CC       interdental cells of the Limbus as well as in Schwann cells and cells
CC       of the cochlear nerve and the spiral ganglions (at protein level). Not
CC       expressed in cells of the inner and outer sulcus or the Reissner's
CC       membrane (at protein level) (PubMed:20627126, PubMed:21364656).
CC       {ECO:0000269|PubMed:10626797, ECO:0000269|PubMed:14741722,
CC       ECO:0000269|PubMed:16329164, ECO:0000269|PubMed:20627126,
CC       ECO:0000269|PubMed:21364656}.
CC   -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent and peaks at
CC       mitosis. {ECO:0000269|PubMed:18591255}.
CC   -!- INDUCTION: Up-regulated by COMP. {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: The BIR repeat is necessary and sufficient for LAMTOR5 binding.
CC       {ECO:0000269|PubMed:12773388}.
CC   -!- PTM: Ubiquitinated by the Cul9-RING ubiquitin-protein ligase complex,
CC       leading to its degradation. Ubiquitination is required for centrosomal
CC       targeting. Deubiquitinated by USP35 or USP38; leading to stabilization
CC       (PubMed:34438346). {ECO:0000269|PubMed:16322459,
CC       ECO:0000269|PubMed:24793696, ECO:0000269|PubMed:34438346}.
CC   -!- PTM: In vitro phosphorylation at Thr-117 by AURKB prevents interaction
CC       with INCENP and localization to mitotic chromosomes (PubMed:14610074).
CC       Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti-
CC       apoptotic activities (PubMed:21252625). Phosphorylation at Thr-34 by
CC       CDK15 is critical for its anti-apoptotic activity (PubMed:24866247).
CC       Phosphorylation at Ser-20 by AURKC is critical for regulation of proper
CC       chromosome alignment and segregation, and possibly cytokinesis.
CC       {ECO:0000269|PubMed:11069302, ECO:0000269|PubMed:14610074,
CC       ECO:0000269|PubMed:21252625, ECO:0000269|PubMed:24866247,
CC       ECO:0000269|PubMed:27332895}.
CC   -!- PTM: Acetylation at Lys-129 by CBP results in its homodimerization,
CC       while deacetylation promotes the formation of monomers which
CC       heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The
CC       acetylated form represses STAT3 transactivation. The dynamic
CC       equilibrium between its acetylation and deacetylation at Lys-129
CC       determines its interaction with XPO1/CRM1, its subsequent subcellular
CC       localization, and its ability to inhibit STAT3 transactivation.
CC       {ECO:0000269|PubMed:20826784}.
CC   -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U75285; AAC51660.1; -; Genomic_DNA.
DR   EMBL; AF077350; AAD34226.1; -; mRNA.
DR   EMBL; AB154416; BAD11155.1; -; mRNA.
DR   EMBL; AY830084; AAW22624.1; -; mRNA.
DR   EMBL; AB028869; BAA93676.1; -; mRNA.
DR   EMBL; AY927772; AAY15202.1; -; mRNA.
DR   EMBL; DQ227257; ABB76601.1; -; mRNA.
DR   EMBL; DQ310375; ABC42341.1; -; mRNA.
DR   EMBL; DQ310376; ABC42342.1; -; mRNA.
DR   EMBL; DQ310377; ABC42343.1; -; mRNA.
DR   EMBL; DQ310378; ABC42344.1; -; mRNA.
DR   EMBL; DQ310379; ABC42345.1; -; mRNA.
DR   EMBL; CR541740; CAG46540.1; -; mRNA.
DR   EMBL; AK223428; BAD97148.1; -; mRNA.
DR   EMBL; AK311917; BAG34858.1; -; mRNA.
DR   EMBL; AY795969; AAV40840.1; -; Genomic_DNA.
DR   EMBL; AC087645; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89514.1; -; Genomic_DNA.
DR   EMBL; BC008718; AAH08718.1; -; mRNA.
DR   EMBL; BC034148; AAH34148.1; -; mRNA.
DR   EMBL; BC065497; AAH65497.1; -; mRNA.
DR   CCDS; CCDS11755.1; -. [O15392-1]
DR   CCDS; CCDS32751.1; -. [O15392-3]
DR   CCDS; CCDS32752.1; -. [O15392-2]
DR   RefSeq; NP_001012270.1; NM_001012270.2. [O15392-3]
DR   RefSeq; NP_001012271.1; NM_001012271.1.
DR   RefSeq; NP_001159.2; NM_001168.2.
DR   PDB; 1E31; X-ray; 2.71 A; A/B=1-142.
DR   PDB; 1F3H; X-ray; 2.58 A; A/B=1-142.
DR   PDB; 1XOX; NMR; -; A/B=1-117.
DR   PDB; 2QFA; X-ray; 1.40 A; A=1-142.
DR   PDB; 2RAW; X-ray; 2.40 A; A=1-142.
DR   PDB; 2RAX; X-ray; 3.30 A; A/E/X=1-120.
DR   PDB; 3UEC; X-ray; 2.18 A; A=1-142.
DR   PDB; 3UED; X-ray; 2.70 A; A/C=1-142.
DR   PDB; 3UEE; X-ray; 2.61 A; A/C=1-142.
DR   PDB; 3UEF; X-ray; 2.45 A; A/C=1-142.
DR   PDB; 3UEG; X-ray; 2.80 A; A/B=1-142.
DR   PDB; 3UEH; X-ray; 2.60 A; A/B=1-142.
DR   PDB; 3UEI; X-ray; 2.70 A; A/B=1-142.
DR   PDB; 3UIG; X-ray; 2.40 A; A/B=1-142.
DR   PDB; 3UIH; X-ray; 2.40 A; A/B=1-142.
DR   PDB; 3UII; X-ray; 2.60 A; A/B=1-142.
DR   PDB; 3UIJ; X-ray; 2.70 A; A/B=1-142.
DR   PDB; 3UIK; X-ray; 2.70 A; A/B=1-142.
DR   PDB; 4A0I; X-ray; 2.60 A; A/B=1-142.
DR   PDB; 4A0J; X-ray; 2.80 A; A/B=1-142.
DR   PDB; 4A0N; X-ray; 2.74 A; A=1-142.
DR   PDB; 6SHO; X-ray; 3.20 A; A/B=1-142.
DR   PDB; 6YIE; X-ray; 3.49 A; A/D=1-142.
DR   PDB; 6YIF; X-ray; 1.81 A; A=1-142.
DR   PDB; 6YIH; X-ray; 2.55 A; A=1-142.
DR   PDB; 7LBK; X-ray; 2.70 A; A/B=1-142.
DR   PDB; 7LBO; X-ray; 2.50 A; A/B=1-142.
DR   PDB; 7LBP; X-ray; 2.60 A; A/C=1-142.
DR   PDB; 7LBQ; X-ray; 2.69 A; A=1-142.
DR   PDB; 8RUP; EM; 2.42 A; K=1-142.
DR   PDBsum; 1E31; -.
DR   PDBsum; 1F3H; -.
DR   PDBsum; 1XOX; -.
DR   PDBsum; 2QFA; -.
DR   PDBsum; 2RAW; -.
DR   PDBsum; 2RAX; -.
DR   PDBsum; 3UEC; -.
DR   PDBsum; 3UED; -.
DR   PDBsum; 3UEE; -.
DR   PDBsum; 3UEF; -.
DR   PDBsum; 3UEG; -.
DR   PDBsum; 3UEH; -.
DR   PDBsum; 3UEI; -.
DR   PDBsum; 3UIG; -.
DR   PDBsum; 3UIH; -.
DR   PDBsum; 3UII; -.
DR   PDBsum; 3UIJ; -.
DR   PDBsum; 3UIK; -.
DR   PDBsum; 4A0I; -.
DR   PDBsum; 4A0J; -.
DR   PDBsum; 4A0N; -.
DR   PDBsum; 6SHO; -.
DR   PDBsum; 6YIE; -.
DR   PDBsum; 6YIF; -.
DR   PDBsum; 6YIH; -.
DR   PDBsum; 7LBK; -.
DR   PDBsum; 7LBO; -.
DR   PDBsum; 7LBP; -.
DR   PDBsum; 7LBQ; -.
DR   PDBsum; 8RUP; -.
DR   AlphaFoldDB; O15392; -.
DR   BMRB; O15392; -.
DR   EMDB; EMD-19513; -.
DR   SASBDB; O15392; -.
DR   SMR; O15392; -.
DR   BioGRID; 106829; 109.
DR   ComplexPortal; CPX-111; Survivin homodimer complex.
DR   ComplexPortal; CPX-116; Chromosomal passenger complex.
DR   CORUM; O15392; -.
DR   DIP; DIP-34662N; -.
DR   ELM; O15392; -.
DR   FunCoup; O15392; 1567.
DR   IntAct; O15392; 56.
DR   MINT; O15392; -.
DR   STRING; 9606.ENSP00000301633; -.
DR   BindingDB; O15392; -.
DR   ChEMBL; CHEMBL5989; -.
DR   DrugBank; DB16095; APG-1387.
DR   DrugBank; DB04115; Berberine.
DR   DrugBank; DB12085; LCL-161.
DR   DrugBank; DB05141; LY2181308.
DR   DrugBank; DB00206; Reserpine.
DR   DrugBank; DB16305; Xevinapant.
DR   DrugCentral; O15392; -.
DR   GuidetoPHARMACOLOGY; 2795; -.
DR   MEROPS; I32.005; -.
DR   iPTMnet; O15392; -.
DR   PhosphoSitePlus; O15392; -.
DR   BioMuta; BIRC5; -.
DR   jPOST; O15392; -.
DR   MassIVE; O15392; -.
DR   PeptideAtlas; O15392; -.
DR   ProteomicsDB; 48627; -. [O15392-1]
DR   ProteomicsDB; 48628; -. [O15392-2]
DR   ProteomicsDB; 48629; -. [O15392-3]
DR   ProteomicsDB; 48630; -. [O15392-4]
DR   ProteomicsDB; 48631; -. [O15392-5]
DR   ProteomicsDB; 48632; -. [O15392-6]
DR   ProteomicsDB; 48633; -. [O15392-7]
DR   Pumba; O15392; -.
DR   ABCD; O15392; 5 sequenced antibodies.
DR   Antibodypedia; 1073; 1826 antibodies from 52 providers.
DR   DNASU; 332; -.
DR   Ensembl; ENST00000374948.6; ENSP00000364086.1; ENSG00000089685.15. [O15392-3]
DR   Ensembl; ENST00000590449.1; ENSP00000465868.1; ENSG00000089685.15. [O15392-7]
DR   Ensembl; ENST00000590925.6; ENSP00000467336.1; ENSG00000089685.15. [O15392-4]
DR   Ensembl; ENST00000592734.5; ENSP00000466617.1; ENSG00000089685.15. [O15392-6]
DR   GeneID; 332; -.
DR   KEGG; hsa:332; -.
DR   UCSC; uc002jvh.4; human. [O15392-1]
DR   AGR; HGNC:593; -.
DR   CTD; 332; -.
DR   DisGeNET; 332; -.
DR   GeneCards; BIRC5; -.
DR   HGNC; HGNC:593; BIRC5.
DR   HPA; ENSG00000089685; Tissue enhanced (bone marrow, lymphoid tissue, testis).
DR   MIM; 603352; gene.
DR   OpenTargets; ENSG00000089685; -.
DR   VEuPathDB; HostDB:ENSG00000089685; -.
DR   GeneTree; ENSGT00510000047537; -.
DR   HOGENOM; CLU_1869818_0_0_1; -.
DR   InParanoid; O15392; -.
DR   OrthoDB; 2196114at2759; -.
DR   PAN-GO; O15392; 6 GO annotations based on evolutionary models.
DR   PathwayCommons; O15392; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; O15392; -.
DR   SIGNOR; O15392; -.
DR   BioGRID-ORCS; 332; 826 hits in 1161 CRISPR screens.
DR   CD-CODE; 3F4CB227; Synthetic Condensate 000322.
DR   CD-CODE; 45F3D8EC; Synthetic Condensate 000342.
DR   CD-CODE; 7230F6EA; Synthetic Condensate 000328.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   ChiTaRS; BIRC5; human.
DR   EvolutionaryTrace; O15392; -.
DR   GeneWiki; Survivin; -.
DR   GenomeRNAi; 332; -.
DR   Pharos; O15392; Tchem.
DR   PRO; PR:O15392; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; O15392; protein.
DR   Bgee; ENSG00000089685; Expressed in ventricular zone and 127 other cell types or tissues.
DR   ExpressionAtlas; O15392; baseline and differential.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0032133; C:chromosome passenger complex; IPI:UniProtKB.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031021; C:interphase microtubule organizing center; IDA:UniProtKB.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; IBA:GO_Central.
DR   GO; GO:1990713; C:survivin complex; IPI:ComplexPortal.
DR   GO; GO:0050897; F:cobalt ion binding; NAS:UniProtKB.
DR   GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IMP:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IBA:GO_Central.
DR   GO; GO:0051303; P:establishment of chromosome localization; IMP:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB.
DR   GO; GO:0090307; P:mitotic spindle assembly; NAS:ComplexPortal.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal.
DR   GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal.
DR   GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal.
DR   GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal.
DR   GO; GO:0031503; P:protein-containing complex localization; IMP:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; IEP:UniProtKB.
DR   CDD; cd00022; BIR; 1.
DR   FunFam; 1.10.1170.10:FF:000009; Baculoviral IAP repeat-containing protein 5; 1.
DR   Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1.
DR   IDEAL; IID00186; -.
DR   InterPro; IPR051190; Baculoviral_IAP.
DR   InterPro; IPR001370; BIR_rpt.
DR   PANTHER; PTHR46771:SF3; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; 1.
DR   PANTHER; PTHR46771; DETERIN; 1.
DR   Pfam; PF00653; BIR; 1.
DR   SMART; SM00238; BIR; 1.
DR   SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1.
DR   PROSITE; PS50143; BIR_REPEAT_2; 1.
DR   neXtProt; NX_O15392; -.
DR   PharmGKB; PA25362; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell cycle;
KW   Cell division; Centromere; Chromosome; Chromosome partition; Cytoplasm;
KW   Cytoskeleton; Host-virus interaction; Kinetochore; Metal-binding;
KW   Microtubule; Mitosis; Nucleus; Phosphoprotein; Protease inhibitor;
KW   Proteomics identification; Reference proteome; Repressor;
KW   Thiol protease inhibitor; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc.
FT   CHAIN           1..142
FT                   /note="Baculoviral IAP repeat-containing protein 5"
FT                   /id="PRO_0000122356"
FT   REPEAT          18..88
FT                   /note="BIR"
FT   BINDING         57
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:17956729,
FT                   ECO:0007744|PDB:2QFA"
FT   BINDING         60
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:17956729,
FT                   ECO:0007744|PDB:2QFA"
FT   BINDING         77
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:17956729,
FT                   ECO:0007744|PDB:2QFA"
FT   BINDING         84
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:17956729,
FT                   ECO:0007744|PDB:2QFA"
FT   SITE            126
FT                   /note="Interaction with FBXL7"
FT                   /evidence="ECO:0000269|PubMed:25778398"
FT   MOD_RES         20
FT                   /note="Phosphoserine; by AURKC"
FT                   /evidence="ECO:0000269|PubMed:27332895"
FT   MOD_RES         23
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         34
FT                   /note="Phosphothreonine; by CDK1 and CDK15"
FT                   /evidence="ECO:0000269|PubMed:11069302,
FT                   ECO:0000269|PubMed:24866247, ECO:0007744|PubMed:18691976"
FT   MOD_RES         48
FT                   /note="Phosphothreonine; by CK2; in vitro"
FT                   /evidence="ECO:0000269|PubMed:21252625"
FT   MOD_RES         90
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         110
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         112
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         115
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         117
FT                   /note="Phosphothreonine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:14610074"
FT   MOD_RES         121
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MOD_RES         129
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   VAR_SEQ         74..142
FT                   /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE
FT                   ETAKKVRRAIEQLAAMD -> MQRKPTIRRKNLRKLRRKCAVPSSSWLPWIEASGRSCL
FT                   VPEWLHHFQGLFPGATSLPVGPLAMS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10626797"
FT                   /id="VSP_020338"
FT   VAR_SEQ         74..142
FT                   /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE
FT                   ETAKKVRRAIEQLAAMD -> MRELC (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.8"
FT                   /id="VSP_020339"
FT   VAR_SEQ         74..142
FT                   /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE
FT                   ETAKKVRRAIEQLAAMD -> M (in isoform 7)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_020340"
FT   VAR_SEQ         74
FT                   /note="I -> IGPGTVAYACNTSTLGGRGGRITR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10626797, ECO:0000303|Ref.6"
FT                   /id="VSP_002454"
FT   VAR_SEQ         105..142
FT                   /note="DRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD -> VRETLPPPRS
FT                   FIR (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:16329164"
FT                   /id="VSP_020341"
FT   VAR_SEQ         114..142
FT                   /note="AKETNNKKKEFEETAKKVRRAIEQLAAMD -> ERALLAE (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:14741722"
FT                   /id="VSP_020342"
FT   VARIANT         129
FT                   /note="K -> E (loss of acetylation; localization primarily
FT                   within the cytoplasm; increased likelihood of existing as
FT                   monomer; stronger binding to XPO1/CRM1; dbSNP:rs2071214)"
FT                   /evidence="ECO:0000269|PubMed:16625196,
FT                   ECO:0000269|PubMed:20826784"
FT                   /id="VAR_021071"
FT   MUTAGEN         18
FT                   /note="R->A: Disrupts interaction with histone H3pT3, no
FT                   effect on interaction with INCENP."
FT                   /evidence="ECO:0000269|PubMed:20929775"
FT   MUTAGEN         23
FT                   /note="K->R: Increases ubiquitination and blocks
FT                   dissociation from centromeres; when associated with R-62;
FT                   R-78 and R-79."
FT                   /evidence="ECO:0000269|PubMed:16322459"
FT   MUTAGEN         25
FT                   /note="W->A: Disrupts interaction with histone H3pT3, no
FT                   effect on interaction with INCENP."
FT                   /evidence="ECO:0000269|PubMed:20929775"
FT   MUTAGEN         33
FT                   /note="C->R: Disrupts interaction with histone H3pT3, no
FT                   effect on interaction with INCENP."
FT                   /evidence="ECO:0000269|PubMed:20929775"
FT   MUTAGEN         34
FT                   /note="T->A: Loss of LAMTOR5 binding."
FT                   /evidence="ECO:0000269|PubMed:12773388"
FT   MUTAGEN         34
FT                   /note="T->E: Higher affinity for LAMTOR5 binding."
FT                   /evidence="ECO:0000269|PubMed:12773388"
FT   MUTAGEN         48
FT                   /note="T->A,E: Localizes normally during mitosis but cannot
FT                   support cell proliferation. Increased affinity for
FT                   CDCA8/borealin."
FT                   /evidence="ECO:0000269|PubMed:21252625"
FT   MUTAGEN         57
FT                   /note="C->A: Disrupts interaction with histone H3pT3, no
FT                   effect on interaction with INCENP."
FT                   /evidence="ECO:0000269|PubMed:20929775"
FT   MUTAGEN         62
FT                   /note="K->R: Increases ubiquitination and blocks
FT                   dissociation from centromeres; when associated with R-23;
FT                   R-78 and R-79."
FT                   /evidence="ECO:0000269|PubMed:16322459"
FT   MUTAGEN         65
FT                   /note="E->A: Almost abolishes RAN-binding. Does not disrupt
FT                   binding to AURKB or CDCA8. Disrupts mitotic spindle
FT                   assembly. Does not disrupt nuclear export."
FT                   /evidence="ECO:0000269|PubMed:18591255"
FT   MUTAGEN         67
FT                   /note="W->A: Disrupts interaction with histone H3pT3, no
FT                   effect on interaction with INCENP."
FT                   /evidence="ECO:0000269|PubMed:20929775"
FT   MUTAGEN         70
FT                   /note="D->A: No change. Loss of interaction with AURKB;
FT                   when associated with A-71."
FT                   /evidence="ECO:0000269|PubMed:16762323"
FT   MUTAGEN         71
FT                   /note="D->A: No change. Loss of interaction with AURKB;
FT                   when associated with A-70."
FT                   /evidence="ECO:0000269|PubMed:16762323"
FT   MUTAGEN         78
FT                   /note="K->R: Increases ubiquitination and blocks
FT                   dissociation from centromeres; when associated with R-23;
FT                   R-62 and R-79."
FT                   /evidence="ECO:0000269|PubMed:16322459"
FT   MUTAGEN         79
FT                   /note="K->R: Increases ubiquitination and blocks
FT                   dissociation from centromeres; when associated with R-23;
FT                   R-62 and R-78."
FT                   /evidence="ECO:0000269|PubMed:16322459"
FT   MUTAGEN         84
FT                   /note="C->A: Loss of cytoprotection."
FT   MUTAGEN         90..91
FT                   /note="KK->RR: Loss of FBXL7 mediated polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:25778398"
FT   MUTAGEN         117
FT                   /note="T->A: Prevents phosphorylation by AURKB. Still able
FT                   to localize correctly but prevents interaction with
FT                   INCENP."
FT                   /evidence="ECO:0000269|PubMed:14610074"
FT   MUTAGEN         117
FT                   /note="T->E: Mimics phosphorylation. Disrupts subcellular
FT                   localization during mitosis and prevents interaction with
FT                   INCENP."
FT                   /evidence="ECO:0000269|PubMed:14610074"
FT   MUTAGEN         126
FT                   /note="E->A: Loss of FBXL7 binding."
FT                   /evidence="ECO:0000269|PubMed:25778398"
FT   MUTAGEN         129
FT                   /note="K->A,Q: Mimics acetylation. Localization primarily
FT                   within the nucleus."
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   MUTAGEN         129
FT                   /note="K->R: Loss of acetylation. Localization primarily
FT                   within the cytoplasm."
FT                   /evidence="ECO:0000269|PubMed:20826784"
FT   CONFLICT        57..58
FT                   /note="CF -> WV (in Ref. 5; AAW22624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="F -> L (in Ref. 11; BAD97148)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        128
FT                   /note="A -> V (in Ref. 9; CAG46540)"
FT                   /evidence="ECO:0000305"
FT   TURN            8..10
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           11..13
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           15..20
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   STRAND          29..32
FT                   /evidence="ECO:0007829|PDB:6YIF"
FT   HELIX           35..40
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   STRAND          43..45
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:3UIG"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   TURN            58..60
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   STRAND          63..65
FT                   /evidence="ECO:0007829|PDB:6YIF"
FT   HELIX           73..80
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:1F3H"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           93..95
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           98..139
FT                   /evidence="ECO:0007829|PDB:2QFA"
SQ   SEQUENCE   142 AA;  16389 MW;  9E7CADCDF2822286 CRC64;
     MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC
     FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK
     KKEFEETAKK VRRAIEQLAA MD
//
